-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNxt Submits EU Clinical Trial Application for Sublingual Cladribine

PUBT·10/19/2026 07:05:37
Listen to the news
BioNxt Submits EU Clinical Trial Application for Sublingual Cladribine
  • BioNxt Solutions submitted a European clinical trial application for BNT23001, its sublingual cladribine film, on October 16, 2026.
  • Regulatory review could take approximately three months; trial initiation requires authorization, ethics approvals and investigational product release.
  • The planned human study will assess pharmacokinetics and bioequivalence against Mavenclad tablets.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNxt Solutions Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610190305ACCESSWRNAPR_____1238227) on October 19, 2026, and is solely responsible for the information contained therein.